Jaka jest cena za GBS Inc. (GBS)

Cena za GBS Inc. (GBS) wynosi $0.4732

Jaka jest kapitalizacja rynkowa dla GBS Inc. (GBS)

Kapitalizacja rynkowa dla GBS Inc. (GBS) wynosi $7.05M

GBS Inc. (GBS) Stopa Dywidendy

Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Rok	Stopa dywidendy	Zmień
Za mało danych dla podanych dat.

Rok

Stopa dywidendy

Zmień

Za mało danych dla podanych dat.

Firma	Stopa dywidendy	Kraj
Abbott Laboratories ABT.US	2.23%	US
Stryker Corporation SYK.US	1.03%	US
Medtronic plc MDT.US	3.69%	IE
Boston Scientific Corporation BSX.US	0.00%	US
Edwards Lifesciences Corporation EW.US	0.00%	US

Firma

Stopa dywidendy

Kraj